Form 4: Clene Inc. Chief Science Officer, Mark Mortenson, Reports Stock Option Grant

Mark Mortenson, Chief Science Officer of Clene Inc., reports the acquisition of stock options for 25,000 shares of common stock.

Summary

• Mark Mortenson, the Chief Science Officer of Clene Inc., filed a Form 4 on August 19, 2024, reporting a transaction.
• On August 16, 2024, Mortenson was granted stock options for 25,000 shares of Clene Inc. common stock at an exercise price of $5.15 per share.
• These options vest in 1/12th increments monthly, starting September 16, 2024, until fully vested.
• Following the reported transaction, Mortenson beneficially owns 25,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing regarding stock options. It's neutral in sentiment, reflecting standard compensation practices.

Positives

• The grant of stock options to the Chief Science Officer aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize key employees and align their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• The size of the grant and the vesting schedule are generally determined based on the executive's role, performance, and industry benchmarks.
• Comparable companies like Biogen, Amgen, and Gilead Sciences also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant could have a minor dilutive effect on existing shareholders.
• The grant incentivizes the Chief Science Officer to contribute to the company's success, potentially benefiting all stakeholders.

Key Dates